新的口服PCSK9抑制剂:"MK-0616"
Zoya Siddiqui1, William Frishman1,2
1From the School of Medicine, New York Medical College, Valhalla, NY.
Cardiology in review
|January 29, 2024
概括
MK-0616是一种口服,有效降低高胆固醇患者的LDL胆固醇. 这种新型的proprotein转化酶亚素/素9型 (PCSK9) 抑制剂显示出作为注射疗法的安全和耐受替代品的希望.
科学领域:
- 心血管药理学心血管药理学
- 药用化学 医学化学
- 临床治疗学 临床治疗学
背景情况:
- 高胆固醇血症的管理往往需要有效的降低LDL-C的疗法.
- 目前的PCSK9抑制剂是可注射的 (单克隆抗体,siRNA),这带来了管理方面的挑战.
- 需要口服可用的,患者友好的降脂剂.
研究的目的:
- 评估MK-0616的安全性,疗效和药理动力学,一种新的口服PCSK9抑制剂.
- 评估MK-0616作为可注射PCSK9抑制剂的替代品的潜力.
- 调查MK-0616在高胆固醇血症患者,包括接受他类药物治疗的患者中的降脂效应.
主要方法:
- 使用创新的合成化学和mRNA显示技术开发MK-0616.
- 1期和2b期临床试验,以评估安全性,耐受性,药理动力学和疗效.
- 对剂量依赖的全身吸收和长半衰期的评估.
- 将LDL-C降低效应与现有的PCSK9抑制剂进行比较.
主要成果:
- MK-0616显示了剂量依赖的全身吸收和长半衰期.
- 与当前的PCSK9抑制剂相比,观察到可比的低密度脂蛋白胆固醇 (LDL-C) 降低疗效.
- 在各种患者群体中报告了良好的耐受性,包括接受他类药物治疗的患者.
结论:
- MK-0616是一种安全有效的口服宏环PCSK9抑制剂,用于高胆固醇血症.
- 它为注射性降脂疗法提供了一个患者友好的替代方案.
- 需要进一步进行第三期试验,以确认其长期疗效和降低心血管风险的潜力.
更多相关视频
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
13.4K
09:43In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis
Published on: August 4, 2011
18.0K
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
454
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
454
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
